Skip to main content
. 2021 Dec;379(3):343–357. doi: 10.1124/jpet.121.000845

Fig. 1.

Fig. 1.

Importance of p53 and MGMT status for berzosertib and TMZ combination in GBM. (A) Increased sensitivity to berzosertib in the case of p53 mutation downstream of the ATR pathway and (B) increased sensitivity to TMZ in the case of MGMT methylation and inactivation, both contributing to prevention of DNA repair and thereby contributing to tumor cell death.